This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Amgen Inc.. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Beate Sable: Innovator in Cancer Treatment
Introduction
Beate Sable is a prominent inventor based in Newbury Park, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic methods. Her work focuses on utilizing biomarkers and selective tyrosine kinase inhibitors to enhance patient outcomes in cancer therapy.
Latest Patents
Beate Sable holds 1 patent related to her groundbreaking work. The patent, titled "Biomarkers and use of MET inhibitor for treatment of cancer," outlines methods for therapeutic treatment of cancer using selective tyrosine kinase inhibitors. This invention emphasizes the importance of cancer biomarkers, such as MET amplification and high Met expression, for patient selection in treatment protocols.
Career Highlights
Throughout her career, Beate has been associated with Amgen Inc., a leading biotechnology company. Her role at Amgen has allowed her to collaborate with other experts in the field and contribute to advancements in cancer research and treatment methodologies.
Collaborations
Beate has worked alongside notable colleagues, including Paul G Hughes and Angela Coxon. These collaborations have fostered an environment of innovation and have led to significant advancements in cancer treatment strategies.
Conclusion
Beate Sable's contributions to cancer treatment through her patented innovations highlight her dedication to improving patient care. Her work continues to influence the field and offers hope for more effective cancer therapies in the future.